Retrospective data Author Year
Age Histologies (WHO) IPI High-dose regimen Status at Tx DFS/EFS/ PFS/RFS OS Followup (months) Comment Vose et al. [22 ] 1990 17 33 No data
No data Diverse CR 42% PR 26% 28% (2 y) 35% (2 y) 28 Fanin et al. [23 ] 1999 64 25 ALCL 100% aaIPI 0/1 48% 2/3 22% Unknown 30% Diverse CR 47% 56% (5 y) 70% (5 y) 43 34/64 transplanted 2.line Rodríguez et al. [24 ] 2001 29 43 No data
0/1 31% 2 41% 3 21% 4/5 7% Diverse CR 38% PR 48% 32% (3 y) 39% (3 y) 43 Blystad et al. [25 ] 2001 40 42 PTCLu 50% ALCL 35% Other 15% aaIPI 0/1 42% 2/3 45% Unknown 13% Diverse CR 70% PR 30% 56% (3 y) 58% (3 y) 25 23/40 transplanted 2.line Song et al. [26 ] 2002 36 46 PTCLu 56% ALCL 25% NK/T 11% Other 8% No data Mel/Eto CR 42% PR 50% 37% (3 y) 48% (3 y) 42 Rodríguez et al. [27 ] 2003 115 41 PTCLu 63% ALCL 22% NK/T 15% aaIP 0/1 40% 2/3 60% Diverse CR 56% PR 38% 60% (5 y) 49% (5 y)
56% (5 y) 45% (5 y)
37 78/115 transplanted 2.line Schetelig et al. [28 ] 2003 29 51 AITL 100% aaIPI 0/1 21% 2/3 79% Diverse No data 37% (5 y) 39% (5 y)
60% (5 y) 44% (5 y)
60 15/29 transplanted 2.line Zamkoff et al. [29 ] 2004 16 52
100%aaIPI 0/1 67% 2/3 33% Diverse CR 60% PR 40% 12 w (median) 72 w (median) No data Jantunen et al. [30 ] 2004 37 46 PTCLu 38% ALCL 38% EATL 14% Other 11% 0/1 46% 2 22% 3 19% 4/5 14% Unknown 3% BEAC/BEAM CR/PR 87% 44% (5 y) 28% (5 y)
54% (5 y) 45% (5 y)
24 19/37 transplanted 2.line TRM 16% Jagasia et al. [31 ] 2004 28 39 ALCL 57% PTCLu 21% AITL 11% NK/T 11% aaIPI 0/1 29% 2/3 50% Unknown 21% Cy/Eto/TBI or CBV CR 39% PR 46% 50% (3 y) 69% (3 y) 44 7/28 underwent alloSCT Kewalramani et al. [32 ] 2006 24 48 PTCLu 58% ALCL 17% AITL 17% Other 8% aaIPI 0/1 46% 2/3 54% Diverse CR 63% PR 37% 24% (5 y) 33% (5 y) 72 Kim et al. [33 ] 2007 40 44 PTCLu 50% NK/T 25% ALCL 13% Other 13% aaIPI 0/1 45% 2/3 53% Unknown 3% Diverse CR 28% PR 52% No data 11.5 m (median) 16 29/40 transplanted 2.line Smith et al. [34 ] 2007 32 44 ALCL 66% PTCLu 34% aaIPI (at Tx) 0/1 72% 2/3 28% BEC No data 18% (5 y) 34% (5 y) 30 26/32 transplanted 2.line Chen et al. [35 ] 2008 53 45 ALCL 34% PTCLu 30% AITL 17% Other 19% No data Diverse CR/PR 89% 25% (5 y) 9% (5 y)
48% (5 y) 37% (5 y)
60 38/53 transplanted 2.line Lee et al. [36 ] 2008 47 42 NK/T 100% aaIPI 0/1 82% 2/3 18% CVB/BEAM/ MCEC (72%) CR 58% No data No data 117 33/47 transplanted 2.line Yang et al. [37 ] 2009 64 44 PTCLu 100% aaIPI 0/1 56% 2/3 44% BEAM/CVB (70%) CR 33% PR 58% 44% (3 y) 33% (3 y)
53% (3 y) 46% (3 y)
30 36/64 transplanted 2.line